Quest Diagnostics
815 hedge funds and large institutions have $13.2B invested in Quest Diagnostics in 2024 Q1 according to their latest regulatory filings, with 87 funds opening new positions, 262 increasing their positions, 314 reducing their positions, and 90 closing their positions.
117% more call options, than puts
Call options by funds: $149M | Put options by funds: $68.6M
23% more capital inflows, than outflows
Capital inflows: $1.3B | Capital outflows: $1.06B
2.76% more ownership
Funds ownership: 86.92% → 89.68% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less first-time investments, than exits
New positions opened: 87 | Existing positions closed: 90
1% less funds holding
Funds holding: 826 → 815 (-11)
17% less repeat investments, than reductions
Existing positions increased: 262 | Existing positions reduced: 314
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
+$194M |
| 2 |
Goldman Sachs
New York
|
+$176M |
| 3 |
8KM
8 Knots Management
Dallas,
Texas
|
+$64.6M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$57.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$54.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$318M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$51.7M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$40.2M |
| 4 |
Renaissance Technologies
New York
|
-$37.4M |
| 5 |
Davis Selected Advisers
Tucson,
Arizona
|
-$37M |
DGX Hedge Fund Activity: Q1 2024 in Review
815 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2024, worth a combined $13.2B — down 2% from $13.5B a quarter earlier.
Sellers outnumbered buyers: 90 funds closed out of DGX and 87 opened new positions — a net loss of 3 holders — while 314 trimmed existing stakes and 262 added.
The largest buyer was Fiduciary Management Inc, opening a new position worth an estimated $194M. The largest seller was T. Rowe Price Associates, cutting an estimated $318M.
- 815 institutional investors held Quest Diagnostics (DGX) as of Q1 2024, down from 826 in Q4 2023.
- Funds reported $13.2B of Quest Diagnostics stock for Q1 2024, down 2% quarter-over-quarter.
- 87 funds opened new Quest Diagnostics positions in Q1 2024 and 90 closed out, a net change of -3 holders.
- The largest Quest Diagnostics buyer in Q1 2024 was Fiduciary Management Inc, an estimated $194M added.
- The largest Quest Diagnostics seller in Q1 2024 was T. Rowe Price Associates, an estimated $318M sold.
Based on aggregated 13F filings for Q1 2024.